About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More

NCT01116648

Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer

Update: This study is active but no longer recruiting subjects

Study identifier: NCT01116648

Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Olaparib (AstraZeneca)

Eligibility

PHASE II:

  • Participants must have histologically or cytologically Grade 2 or 3 (high-grade) papillary-serous or endometrioid epithelial ovarian cancer, primary peritoneal serous cancer, or fallopian tube cancer; participants with epithelial ovarian, primary peritoneal, or fallopian tube cancers of other high-grade histologies who carry a known deleterious BRCA germline mutation by standard clinical testing (Myriad BRAC Analysis) will also be considered eligible
  • Participants in the Phase II portion of the trial must have measurable disease by RECIST 1.1 criteria
  • Breast cancer participants must have measurable disease by RECIST criteria

PRIOR THERAPY PHASE II:

  • Prior chemotherapy must have included a first-line platinum-based regimen with or without intravenous consolidation chemotherapy
  • Prior hormonal-based therapy for ovarian, primary peritoneal serous, or fallopian tube cancer is acceptable
  • Patients may not have previously received a PARP-inhibitor. Prior treatment with BSI-201 is allowed
  • Patients may not have had a prior anti-angiogenic agent in the recurrent setting
  • Patients may have received up to 1 non-platinum-based line of therapy in the recurrent setting
  • Patients may have received an unlimited number of platinum-based therapies in the recurrent setting
  • Patients should have platinum-sensitive disease, where platinum-sensitive disease is defined as having had a > 6 month interval since last receiving platinum therapy prior to disease recurrence; patients must have had a prior response while on the platinum-containing regimen and cannot have experienced disease progression while receiving platinum

Type of study:

Phase II study

Treatment:

Breast cancer patients who enroll will receive both cediranib and olaparib.

Study sites:

California
Los Angeles
Cedars-Sinai Medical Center
Contact: M. W. Audeh 310-423-1188 william.audeh@cshs.org

Illinois
Chicago
University of Chicago Comprehensive Cancer Center
Contact: Gini F. Fleming 773-702-6712 gfleming@medicine.bsd.uchicago.edu

Decatur
Decatur Memorial Hospital
Contact: James L. Wade 217-876-4740 kcheek@dmhhs.org

Evanston
Evanston CCOP-NorthShore University HealthSystem
Contact: Bruce E. Brockstein 847-570-1381 bbrockstein@northshore.org

Harvey
Ingalls Memorial Hospital Recruiting
Contact: Sulochana D. Yalavarthi 708-339-4800 sulochana2001@hotmail.com

Maywood
Loyola University Medical Center
Contact: Joseph I. Clark 708-226-4357 jclark@lumc.edu

Peoria
Illinois CancerCare-Peoria
Contact: James A. Knost 309-243-3000 jknost@illinoiscancercare.com

Springfield
Southern Illinois University
Contact: Krishna A. Rao 217-545-5817 krao@siumed.edu

Central Illinois Hematology Oncology Center
Contact: Sachdev P. Thomas 309-243-3000 sthomas@illinoiscancercare.com

Indiana
Fort Wayne
Fort Wayne Medical Oncology and Hematology Inc - State Boulevard
Contact: Sreenivasa R. Nattam 260-484-8830 ledgar@fwmoh.com

Maryland
Baltimore
Johns Hopkins University
Contact: Deborah K. Armstrong 410-614-2743 darmstro@jhmi.edu

University of Maryland Greenebaum Cancer Center
Contact: Martin J. Edelman 800-888-8823 medelman@umm.edu

Massachusetts
Boston
Beth Israel Deaconess Medical Center
Contact: Mary F. Bussey 617-667-1395 mbuss@bidmc.havard.edu

Dana-Farber Cancer Institute
Contact: Joyce F. Liu 617-632-5269 joyce_liu@dfci.harvard.edu

Massachusetts General Hospital Cancer Center
Contact: Michael J. Birrer 617-724-4800 mbirrer@partners.org

Newton
Newton-Wellesley Hospital
Contact: Caroline C. Block 617-658-6000 cblock@partners.org

Michigan
Ann Arbor
University of Michigan University Hospital
Contact: Maha H. Hussain 800-865-1125 mahahuss@umich.edu

Missouri
Saint Louis
Saint John's Mercy Medical Center
Contact: Bethany G. Sleckman 913-948-5588 Bethany.Sleckman@Mercy.Net

New York
New York
Memorial Sloan Kettering Cancer Center
Contact: William P. Tew 212-639-6555 teww@mskcc.org

Wisconsin
Froedtert and the Medical College of Wisconsin
Contact: Stuart J. Wong 414-805-4380 swong@mcw.edu

Page updated 07/08/13


Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us

Morphtek

This site has been made possible by a generous grant from Morphotek.


Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org